| Autor: |
Philippe Gevaert, Stella E Lee, Russell A Settipane, Martin Wagenmann, Jérôme Msihid, Shahid Siddiqui, Scott Nash, Juby A Jacob‐Nara, Asif H Khan, Siddhesh Kamat, Chien‐Chia Chuang |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Clinical & Translational Immunology, Vol 12, Iss 1, Pp n/a-n/a (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2050-0068 |
| DOI: |
10.1002/cti2.1433 |
| Popis: |
Abstract Objectives To evaluate within‐patient symptom improvement in the dupilumab SINUS‐24/‐52 studies in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) (NCT02912468/NCT02898454). Methods Patients received dupilumab 300 mg or placebo every 2 weeks for 24 (SINUS‐24) or 52 weeks (SINUS‐52) on background intranasal corticosteroids. Patients daily reported symptoms of nasal congestion (NC), loss of smell (LoS) and rhinorrhoea on a scale of 0–3 (0 – no symptoms, 1 – mild, 2 – moderate, 3 – severe symptoms). The proportions of patients with moderate‐to‐severe symptoms (score ≥ 2) at baseline who improved to no‐to‐mild symptoms (score ≤ 1) were determined at Weeks 2, 24 (pooled studies) and 52 (SINUS‐52). Subgroups with prior sinonasal surgery and coexisting asthma were analysed. Results At baseline in the pooled intention‐to‐treat population (n = 724), the proportions of patients with scores ≥ 2 for NC, LoS and rhinorrhoea were 87, 94 and 64%, respectively. Significantly, more patients achieved scores ≤ 1 (no/mild symptoms) with dupilumab vs placebo for each symptom at each time point {Week 2 NC 12% vs 2% [odds ratio 8.9 (95% CI 3.0–26.3)], LoS 5% vs 1% [4.6 (1.3–16.8)], rhinorrhoea 9% vs 2% [4.8 (1.5–15.4)], all P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
